Visomitin 0.155 mcg/ml SkQ1 bottle eye drops 5 ml MitoQ

They are used to correct initial age-related cataracts and dry eye syndrome. They have antioxidant and keratoprotective effects. Based on Skulachev ions – active compounds that protect the mitochondrial cell’s energy stations from oxidative stress.Method of administration and dosageDry eye syndrome: 1-2 drops of the drug in the conjunctival sac 3 times a day. The duration of the course of treatment is determined by the doctor depending on the severity of the disease.Initial stage of age-related cataract: 1-2 drops of the drug in the conjunctival sac 3 times a day. The duration of the course of treatment is 6 months. During therapy with the drug, it is necessary to monitor the ophthalmologist in order to assess the degree of progression of the disease and the need to continue conservative therapy.Indications-Dry eye syndrome.-Initial stage of age-related cataract.CompositionComposition per 1 ml:Active substance:Plastoquinonyldecyltriphenylphosphonium bromide (PDTP) 0.155 mcgExcipients:Benzalkonium chloride 0.1 mg, hypromellose 2 mg, sodium chloride 9 mg, sodium dihydrogen phosphate dihydrate 0.81 mg, sodium hydrogen phosphate dodecahydrate 1.16 mg, sodium hydroxide 1 M solution to pH 6.3 - 7.3, purified water to 1 ml.ContraindicationsHypersensitivity to the components of the drug, age under 18 years.PREGNANCY AND LACTATIONAdequate controlled studies in pregnant and lactating women have not been conducted. It is not recommended to prescribe the drug during pregnancy. If it is necessary to prescribe during lactation, breastfeeding should be discontinued for the period of treatment.Special instructionsEffect on ability to drive vehicles and operate machineryIf short-term blurred vision occurs after using the drug, it is not recommended to drive vehicles or engage in activities that require increased concentration until it is restored.CollapsePackaging and release formEye drops with a concentration of 0.155 mcg/ml in 5 ml polyethylene bottles with dropper stoppers and screw caps. Each bottle with instructions for use is placed in a cardboard box.Side effectsAllergic reactions.Sensory organs: a short-term burning sensation and stinging in the eyes after instillation is possible.INFORM YOUR DOCTOR ABOUT ANY ADVERSE REACTIONS OR SENSATIONS, INCLUDING THOSE NOT MENTIONED IN THESE INSTRUCTIONS, AS WELL AS ANY CHANGES IN LABORATORY INDICATORS DURING THERAPY.Pharmacotherapeutic groupkeratoprotective agentDrug interactionsIf necessary, it can be used simultaneously with other eye drops. In this case, the interval between instillations should be at least 5 minutes.PharmacodynamicsPlastoquinonyldecyltriphenylphosphonium bromide (PDTP) is a plastoquinone derivative, which is linked to a triphenylphosphine residue via a linker chain (C10). PDTP in low (nanomolar) concentrations exhibits high antioxidant activity. It also stimulates the process of tear production, epithelialization, and helps to increase the stability of the tear film.One of the causes of age-related cataracts is the damaging effect of ultraviolet radiation, which initiates photooxidation processes leading to denaturation of the main structural component of the lens - crystallins. The first defense of eye tissues from ultraviolet radiation is the lacrimal fluid, which absorbs ultraviolet light in the range of 240-320 nm and neutralizes it due to the components of the antioxidant activity of the lacrimal fluid. According to preclinical studies, the anti-cataract effect of Vizomitin® is associated with an increase in the expression level of the main lens proteins - ?-crystallins, restoration of the lens epithelium and activation of energy processes in it. According to a clinical study, patients with age-related cataracts who used Vizomitin® showed an increase in the antioxidant activity of tears.Storage temperaturefrom 2℃ to 8℃Dosage formTransparent or slightly opalescent, colorless or slightly colored liquid.PharmacokineticsPharmacokinetics studies in humans have not been conducted. In preclinical studies on animals, PDTF distribution in organs and tissues occurred within